RHOLISTIQ Trademark

Trademark Overview

On Wednesday, August 5, 2020, a trademark application was filed for RHOLISTIQ with the United States Patent and Trademark Office. The USPTO has given the RHOLISTIQ trademark a serial number of 90095950. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 7, 2024. This trademark is owned by Kadmon Pharmaceuticals, LLC. The RHOLISTIQ trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system; pharmaceutical preparations for the prevention and treatment of inflammatory diseases; pharmaceutical preparations for the prevention and treatment of fibrotic diseases and disorders
rholistiq

General Information

Serial Number90095950
Word MarkRHOLISTIQ
Filing DateWednesday, August 5, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 6, 2021

Trademark Statements

Goods and Servicespharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system; pharmaceutical preparations for the prevention and treatment of inflammatory diseases; pharmaceutical preparations for the prevention and treatment of fibrotic diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 4, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameKadmon Pharmaceuticals, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressWarrendale, PA 15086
Party NameKadmon Pharmaceuticals, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressWarrendale, PA 15086

Trademark Events

Event DateEvent Description
Saturday, August 8, 2020NEW APPLICATION ENTERED
Friday, September 4, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, November 10, 2020ASSIGNED TO EXAMINER
Friday, November 13, 2020NON-FINAL ACTION WRITTEN
Friday, November 13, 2020NON-FINAL ACTION E-MAILED
Friday, November 13, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 6, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 6, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 7, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 27, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 16, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 6, 2021PUBLISHED FOR OPPOSITION
Tuesday, July 6, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 31, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, February 26, 2022SOU TEAS EXTENSION RECEIVED
Saturday, February 26, 2022SOU EXTENSION 1 FILED
Saturday, February 26, 2022SOU EXTENSION 1 GRANTED
Tuesday, March 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 24, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, August 24, 2022SOU EXTENSION 2 FILED
Wednesday, August 24, 2022SOU EXTENSION 2 GRANTED
Friday, August 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 28, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, February 28, 2023SOU EXTENSION 3 FILED
Tuesday, February 28, 2023SOU EXTENSION 3 GRANTED
Thursday, March 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 30, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 30, 2023SOU EXTENSION 4 FILED
Wednesday, August 30, 2023SOU EXTENSION 4 GRANTED
Friday, September 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 28, 2024SOU EXTENSION 5 GRANTED
Wednesday, February 28, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 28, 2024SOU EXTENSION 5 FILED
Thursday, February 29, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 7, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, October 7, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

rholistiq pharmaceutical treatment diseases preparations prevention disorders fibrotic inflammatory autoimmune system